

Martin Ullrich

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/528574/publications.pdf>

Version: 2024-02-01

18
papers

380
citations

933447

10
h-index

839539

18
g-index

18
all docs

18
docs citations

18
times ranked

504
citing authors

#	ARTICLE	IF	CITATIONS
1	Personalized drug testing in human pheochromocytoma/paraganglioma primary cultures. <i>Endocrine-Related Cancer</i> , 2022, 29, 285-306.	3.1	12
2	Clickable Albumin Binders for Modulating the Tumor Uptake of Targeted Radiopharmaceuticals. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 710-733.	6.4	13
3	HIF2 α -Associated Pseudohypoxia Promotes Radioresistance in Pheochromocytoma: Insights from 3D Models. <i>Cancers</i> , 2021, 13, 385.	3.7	10
4	Radiolabelled Cyclic Bisarylmercury: High Chemical and in vivo Stability for Theranostics. <i>ChemMedChem</i> , 2021, 16, 2645-2649.	3.2	3
5	Men who stare at bone: multimodal monitoring of bone healing. <i>Biological Chemistry</i> , 2021, 402, 1397-1413.	2.5	3
6	Three-Dimensional Cell Culture Systems in Radiopharmaceutical Cancer Research. <i>Cancers</i> , 2020, 12, 2765.	3.7	32
7	Recent Insights in Barium-131 as a Diagnostic Match for Radium-223: Cyclotron Production, Separation, Radiolabeling, and Imaging. <i>Pharmaceuticals</i> , 2020, 13, 272.	3.8	25
8	Deuteration versus ethylation strategies to improve the metabolic fate of an ¹⁸ F-labeled celecoxib derivative. <i>RSC Advances</i> , 2020, 10, 38601-38611.	3.6	6
9	HIF2 α supports pro-metastatic behavior in pheochromocytomas/paragangliomas. <i>Endocrine-Related Cancer</i> , 2020, 27, 625-640.	3.1	33
10	Current Management of Pheochromocytoma/Paraganglioma: A Guide for the Practicing Clinician in the Era of Precision Medicine. <i>Cancers</i> , 2019, 11, 1505.	3.7	120
11	Targeting Cyclooxygenase-2 in Pheochromocytoma and Paraganglioma: Focus on Genetic Background. <i>Cancers</i> , 2019, 11, 743.	3.7	6
12	Impact of Extrinsic and Intrinsic Hypoxia on Catecholamine Biosynthesis in Absence or Presence of Hif2 α in Pheochromocytoma Cells. <i>Cancers</i> , 2019, 11, 594.	3.7	24
13	Fluorescent mouse pheochromocytoma spheroids expressing hypoxia-inducible factor 2 alpha: Morphologic and radiopharmacologic characterization. <i>Journal of Cellular Biotechnology</i> , 2019, 5, 135-151.	0.5	8
14	Strain-specific metastatic phenotypes in pheochromocytoma allograft mice. <i>Endocrine-Related Cancer</i> , 2018, 25, 993-1004.	3.1	6
15	Diverse effects of phospholipase A2 receptor expression on LNCaP and PC-3 prostate cancer cell growth in vitro and in vivo. <i>Oncotarget</i> , 2018, 9, 35983-35996.	1.8	9
16	An orthotopic xenograft model for high-risk non-muscle invasive bladder cancer in mice: influence of mouse strain, tumor cell count, dwell time and bladder pretreatment. <i>BMC Cancer</i> , 2017, 17, 790.	2.6	16
17	Multimodal Somatostatin Receptor Theranostics Using [⁶⁴ Cu]Cu-/[¹⁷⁷ Lu]Lu-DOTA-(Tyr ³)octreotate and AN-238 in a Mouse Pheochromocytoma Model. <i>Theranostics</i> , 2016, 6, 650-665.	10.0	38
18	In Vivo Fluorescence Imaging and Urinary Monoamines as Surrogate Biomarkers of Disease Progression in a Mouse Model of Pheochromocytoma. <i>Endocrinology</i> , 2014, 155, 4149-4156.	2.8	16